<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Dyax Corporation</title>
	<atom:link href="http://www.stockbloghub.com/tag/dyax-corporation/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(CBST) Cubist Pharmaceuticals Ends Drug Trial</title>
		<link>http://www.stockbloghub.com/2010/04/01/cbst-cubist-pharmaceuticals-ends-drug-trial/32587</link>
		<comments>http://www.stockbloghub.com/2010/04/01/cbst-cubist-pharmaceuticals-ends-drug-trial/32587#comments</comments>
		<pubDate>Thu, 01 Apr 2010 16:23:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[DYAX]]></category>
		<category><![CDATA[Dyax Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32587</guid>
		<description><![CDATA[Cubist Pharmaceuticals Inc. (CBST) has stopped a mid-stage trial of one of its pipeline candidates, CB-500,929 (ecallantide). The drug was being studied for lowering blood loss in patients undergoing cardiac surgery using cardiopulmonary bypass (CPB). The decision to stop the trial was taken following a review of safety and efficacy data from two phase II trials – CONSERV 1 and CONSERV 2. However, this does not impact the 2010 R&#38;D cost guidance as it did not include the cost of development of ecallantide beyond the CONSERV trials. The CONSERV 1 trial was conducted on 249 patients undergoing Coronary Artery Bypass Graft (CABG) Surgery using CPB. No improvement in blood loss was observed in patients who were administered CB-500,929 in three dosages of 5, 25 or 75 mg compared to placebo. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/01/cbst-cubist-pharmaceuticals-ends-drug-trial/32587/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CBST) Cubist to Aquire Calixa Therapeutics</title>
		<link>http://www.stockbloghub.com/2009/12/16/cbst-cubist-to-aquire-calixa-therapeutics/23005</link>
		<comments>http://www.stockbloghub.com/2009/12/16/cbst-cubist-to-aquire-calixa-therapeutics/23005#comments</comments>
		<pubDate>Wed, 16 Dec 2009 22:43:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[DYAX]]></category>
		<category><![CDATA[Dyax Corporation]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23005</guid>
		<description><![CDATA[Recently, Cubist Pharmaceuticals (CBST) decided to acquire a privately held biopharmaceutical company Calixa Therapeutics for an upfront payment of $92.5 million. Additionally, Cubist would be required to make a payment of another $310 million on the achievement of certain development, regulatory, and commercial milestones. Calixa is primarily focused on the development of antibiotics to treat serious bacterial infections. The deal is expected to close by year end. Following the deal, Cubist will gain rights to Calixa’s lead compound CXA-201 (containing CXA-101), an intravenous treatment in mid-stage trial for the treatment of urinary tract and intra-abdominal infections caused by Pseudomonas aeruginosa. In addition, Cubist will also receive rights to another compound CXA-101 and any other drugs incorporating CXA-101, which was acquired from Astellas Pharma. Cubist plans to begin clinical studies of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/16/cbst-cubist-to-aquire-calixa-therapeutics/23005/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

